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Introduction: Selected patients with isolated breast cancer liver metastases (BCLM) may benefit from
surgical management; however, indications remain unclear and the risks may outweigh the benefits in
patients with a generally poor prognosis.
Methods: Between 1998 and 2006, 17 patients diagnosed with BCLM were considered for surgical
management (<4 tumours, tumour <4 cm in diameter and no/stable extrahepatic metastases). Peri-
operative and outcomes data were analysed and compared.
Results: Eight patients were found to have extensive or untreatable disease on staging laparoscopy and
intra-operative ultrasound (SL/IOUS). The remaining nine patients underwent surgical management
[seven laparoscopic radiofrequency ablations (RFA) and two hepatic resections]. Median length of
follow-up for patients treated surgically was 40.0 months, median disease-free survival (DFS) was 32.2
months and median time to disease progression was 17.7 months. Of the eight patients not amenable to
surgery, median length of follow-up was 21.8 months.
Conclusion: SL/IOUS prevented unnecessary laparotomy in half of the patients taken to the operating
room for surgical treatment of BCLM. In patients with BCLM, SL/IOUS should be considered standard of
care before surgical intervention. The small number of patients and short follow-up may be inadequate to
determine the true value of surgical management in this group of patients with BCLM.
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Introduction
Of the 192 000 North Americans who develop breast cancer every
year, approximately 15% will develop liver metastases.1 The
overall prognosis for these patients is poor, with treatment options
usually limited to chemotherapy or hormonal treatments. To
further complicate matters, metastatic breast tumours rarely
maintain oestrogen and progesterone receptor positivity, limiting
the effectiveness of hormonal treatments.2 Even in the best series,
including optimized medical treatment, the median survival is
low.3–8 The one subset of this population that may have additional
treatment options are the 4–5% of patients with breast cancer
metastases limited to the liver.9 These patients have the potential
to be managed surgically, with either hepatic resection or radiof-
requency ablation (RFA).
Several case series have reported an improvement in survival
for patients who underwent hepatic resection for liver-only meta-
static disease, with 5-year survival rates ranging from 9% to
61%.10,11 The majority of patients treated with resection had
limited disease, usually less than four tumours distributed advan-
tageously to allow for complete tumour resection. Many breast
cancer patients, however, are poor candidates for a major surgical
intervention. RFA is a minimally invasive procedure which offers
a low-risk alternative to resection for the definitive treatment of
liver tumours. When properly applied, RFA results in the complete
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focal destruction of the target tumour and a margin of normal
tissue. RFA can be performed either percutaneously or under
surgical guidance. Percutaneous RFA is less invasive than surgical
RFA; however, surgery has the advantages of allowing for more
accurate staging of the disease, more aggressive ablation without
the risk of injury to surronding structures, and if performed lap-
aroscopically, adds only minimal morbidity.12 While the use of
RFA for the treatment of breast cancer liver metastases has been
anecdotally described, its role remains poorly defined.12–19
The present study reviews a single institution’s experience with
the surgical staging and selective treatment of breast cancer meta-
static to the liver using hepatic resection and laparoscopic RFA.
Outcomes of patients who underwent surgical management of
BCLM with an intention to treat are compared to a review of the
existing published literature.
Methods
Between December 1998 and August 2006, 17 patients diagnosed
with breast cancer with metastases limited to the liver were con-
sidered for surgical management with either laparosopic RFA or
hepatic resection. All procedures were performed by a single
surgeon, and data were obtained retrospectively from an insitu-
tional review board (IRB)-approved hospital database.
Patient selection
Pre-operative work-up included a history and physical, complete
blood count, complete metabolic panel and tumour marker
studies. All patients underwent a three-phase computed tomog-
raphy (CT) or magnetic resonance image (MRI) scan to assess
tumour burden in the liver before sugery was considered.
Patients were typically considered for surgical management if
they had limited co-morbidities, four or fewer liver tumours and
no (or limited and stable) extrahepatic disease on pre-operative
imaging. Based largely on our experience with colorectal liver
metastases, patients were preferentially considered for laparo-
scopic RFA if they had significant co-morbidities, four or fewer
liver tumours all <4 cm in size, tumours located more than 1 cm
from the central biliary structures and no (or limited and stable)
extrahepatic disease on pre-operative imaging. Hormone receptor
and HER2 status was not a determining factor for patient selec-
tion. Pre-operative chemotherapy was used at the discretion of the
referring oncologist or surgeon. All patients were presented and
discussed at a multidisciplinary tumour board.
All patients were taken to the operating room for a planned
staging laparoscopy and intra-operative ultrasound (IOUS).
Patients then underwent treatment with either laproscopic radiof-
requency ablation or hepatic resection at the discretion of the
surgeon. If patients did not meet criteria for either laparoscopic
RFA or hepatic resection, the procedure was aborted. These
patients were followed in clinic 2 weeks post-operatively to record
acute surgical outcomes, and were then referred back to their
oncologist for consideration of systemic chemotherapy.
Surgical technique: hepatic resection
Hepatic resection was performed using standard techniques for
either anatomic or non-anatomic resection. After the completion
of laparoscopic staging, a determination was made regarding the
best approach, open or laparoscopic. The ligamentous attach-
ments of the liver were divided for complete mobilization. Extra-
parenchymal division of the portal pedicle and hepatic venous
outflow was performed and the parenchyma was divided with a
combination of ultrasonic coagulation, electrocautery or surgical
stapling.
Surgical technique: laparoscopic RFA
Laparoscopic RFA is a minimally invasive technique performed
under general anaesthesia, which uses a high-frequency alternat-
ing current to produce heat, resulting in local tumour destruction.
All of the patients underwent a diagnostic staging laparoscopy
including IOUS before treatment with RFA. In the absence of
extrahepatic disease, the RFA probe is placed into the tumour
under ultrasound guidance and the probe is deployed into the
tumour bed. The tumour tissue is heated to at least 60°C ensuring
complete cell death is achieved. A double ablation of each tumour
is routinely performed by retracting the RFA probe tines after the
first ablation, turning the shaft of the device 30° and redeploying
the tines into the tumour and repeating the ablation. The treat-
ment goal is to destroy the tumour and a 1-cm margin of normal
liver tissue circumferentially. If the tumour and required margins
are larger than the maximal diameter of the ablation probe, a
series of overlapping ablations are performed. All laparoscopic
RFA procedures were performed using either the RITA XL or
RITA XLi ablation device (RITA Medical Systems Inc., Mountain
View, CA, USA).
Tumour response and follow-up
Surgical follow-up for all patients included a post-operative visit
with a CT scan at 2 weeks (new baseline), subsequent follow-up
visits and repeat imaging studies every 3 months for 2 years and
then every 6 months until 5 years. Complete tumour response was
defined as the absence of arterial enhancement within or at the
periphery of all treated tumours on post-operative imaging. Adju-
vant systemic chemotherapy was offered at the discretion of the
medical oncologist.
Data collection and analysis
Patient demographics, procedural data, complication data and
recurrence data were obtained from an IRB-approved hospital
database. All data were analysed using SPSS 17.0 (SPSS Inc.,
Chicago, IL, USA).
Results
Demographics
Seventeen patients diagnosed with breast cancer metastatic to the
liver were considered for surgical management. The median
patient age was 59.4 years (range, 41.1–67.1), and all patients were
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female. All patients were sent for surgical evaluation because of
either newly identified liver metastases or progression of existing
metastases on chemotherapy. Fourteen patients had metastatic
disease confined to the liver, two patients had concurrent
metastases to the bone and one patient had a concurrent metasta-
sis to the lung. Extrahepatic disease had been stable on pre-
operative imaging for more than 6 months before surgical
treatment. All patients had undergone a resection of their primary
breast cancer (nine lumpectomy and eight mastectomy) before
the diagnosis of liver metastases. Six patients had positive axillary
nodes at the time of the resection for primary cancer, eight
patients had primary tumours that were oestrogen-receptor
positive and two patients had primary tumours that were
progesterone-receptor positive. HER2 status was available for only
nine patients, three of which were HER2 positive. Sixteen patients
had undergone prior treatment with systemic chemotherapy and
radiation for their primary breast cancer. The median number of
months between diagnosis of primary breast cancer and subse-
quent liver metastases was 44.6 months (range, 1.0–231.2). The
median number of liver metastases identified on pre-operative
three-phase CT-scan or MRI was one tumour (range, 1–4) and the
median tumour size was 3.3 cm (range, 1.3–5.0). Pre-operative
patient demographics and prior treatment data are summarized
in Table 1. Three patients had an American Association of Anes-
thesiologists (ASA) classification of 2, 10 patients had an ASA of 3
and four patients had an ASA of 4.
Procedure
Eight patients were deemed inelligible to undergo treatment upon
exploratory laparoscopy and IOUS (unresectable or un-ablatable
disease), and the procedures were aborted. Seven patients under-
went complete ablation of all metastatic lesions with laparoscopic
RFA, and two patients underwent hepatic resection.
Of the patients who underwent treatment with laparoscopic
RFA, the median number of tumours ablated was 1 (range, 1–6),
and the median tumour size was 3.0 cm (range, 1.6–5.9). The
median procedure time for staging laparoscopy, IOUS and RFA
was 157 min (range, 105–245), and median blood loss was 50 ml
(range, 0.0–150.0). Post-operatively, the median length of stay was
2 days (range, 1–9 days).
Two patients underwent hepatic resection (one laparoscopic
left lateral hepatic segmentectomy and one open formal left hepa-
tectomy with caduate lobe resection). Both patients presented
with a single hepatic metastasis less than 5 cm in largest diameter.
The median procedure time for staging laparoscopy, IOUS and
hepatic resection was 325 min (range, 356–413), and blood loss
was less than 750 ml in both patients. The first patient was dis-
charged on post-operative day 2, and the second patient was dis-
charged on post-operative day 3.
Eight patients were found to have extensive disease within the
liver on staging laparoscopy and IOUS that was not amenable to
either laparoscopic RFA or hepatic resection. Five of these patients
were found to have more than 10 tumours on laparoscopy, dis-
Table 1 Patient demographics and pre-operative data for patients with breast cancer liver metastases
No. Age
(years)
Primary
breast
surgery
Positive
axillary
nodes
ER/PR HER2 Chemotherapy
and radiation
for primary
Months between
primary and
diagnosis of
liver metastases
No. of
tumors on
pre-operative
CT
Max diameter
of lesions on
pre-operative
CT (cm)
Concurrent
distant
metastases
1 66 Lumpectomy No +/- - Yes 178.6 1 1.8 None
2 59 Lumpectomy No +/+ NR Yes 231.2 1 2.0 None
3 43 Lumpectomy No +/- + Yes 49.5 4 2.0 None
4 60 Lumpectomy No +/+ NR None 222.2 4 3.0 None
5 41 Mastectomy No -/- - Yes 30.0 1 4.0 None
6 59 Lumpectomy Yes -/- - Yes 42.7 1 5.0 Bone
7 59 Mastectomy Yes -/- NR Yes 1.0 2 3.0 Bone
8 46 Mastectomy No -/- - Yes 36.1 1 2.0 None
9 60 Lumpectomy Yes -/- - Yes 42.7 1 5.0 None
10 53 Lumpectomy Yes +/- + Yes 44.7 1 1.3 None
11 62 Lumpectomy Yes +/- NR Yes 9.7 1 4.5 Lung
12 45 Mastectomy No -/- NR Yes 36.1 1 2.0 None
13 41 Mastectomy No +/- + Yes 49.1 1 2.0 None
14 61 Lumpectomy Yes +/- + Yes 46.0 1 4.0 None
15 56 Mastectomy No -/- - Yes 76.6 2 2.2 None
16 67 Mastectomy No -/- NR Yes 115.4 2 4.0 None
17 50 Mastectomy No -/- NR Yes 13.2 1 4.0 None
ER, oestrogen receptor; PR, progesterone receptor; CT, computed tomography; RFA, radiofrequency ablation; NR, not reported.
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tributed throughout both the left and right hepatic lobes. One
patient was a poor surgical candidate, and was found to have a
large tumour adjacent to the central biliary structures that was
deemed unsafe for ablation. Another patient presented with six
tumours, one of which was greater than 4 cm in diameter on
intra-operative ultrasound. The final patient was found to have
portal lymph nodes positive for poorly differentiated adnocarci-
noma on intra-operative biopsy.
One major complication was reported in a patient who under-
went laparoscopic RFA. The patient suffered a pulmonary
embolus on post-operative day 5 which required anticoagulation,
and was discharged home on post-operative day 9. No complica-
tions were reported in patients who underwent hepatic resection,
or staging laparoscopy alone.
Procedural and outcomes data for all patients are summarized
in Table 2.
Survival and disease recurrence
The median length of follow-up for patients who underwent sur-
gical treatment with either laparoscopic RFA or hepatic resection
was 40.0 months, and the median disease-free survival was 32.2
months.
Of the patients who underwent surgical treatment with laparo-
scopic RFA, five patients developed disease recurrence within the
liver. None of these recurrences, however, were located at an RFA
site. One patient also developed distant metastases to the lymph
nodes and bone. The median time to disease progression within the
liver after laparoscopic RFA was 17.7 months. All patients with
disease recurrence went on to have systemic chemotherapy for
further management of disease. Of the patients who underwent
hepatic resection, one patient presented with disease recurrence
within the liver at 8.0 months, and died at 9.9 months post-
operatively. This patient chose to undergo palliative chemotherapy
after the diagnosis of disease recurrence. The second patient
remained disease-free, and died at 65 months of unrelated causes.
Of the eight patients who were not amenable to either laparo-
scopic RFA or hepatic resection, the median length of follow-up
was 21.8 months. All patients were referred to an oncologist for
further management of their disease, and subsequent treatment
with systemic chemotherapy was offered at the discretion of the
oncologist. Five patients underwent systemic chemotherapy, and
three patients declined further treatment.
Discussion
There are limited data in the published literature evaluating the
use of local surgical therapies for the treatment of BCLM. Hepatic
resection has traditionally been considered the ‘gold standard’ for
management of any primary and metastatic disease within the
liver, however, it is estimated that only 1–3% of these patients are
candidates for hepatic resection.20,21 Hepatic resection carries a
moderate risk of peri-operative morbidity, and to be eligible
patients must have limited co-morbidities and a tumor distribu-
tion within the liver which allows for an adequate functional
Table 2 Procedural and outcomes data for patients with breast cancer liver metastases
No. Procedure (liver metastasis) ASA No. of
tumours on
laparoscopy
Greatest
diameter
of largest
tumour (cm)
LOS Disease
progression
Months to
disease
progression
after RFA/HR
Months of
follow-up
Deceased
1 RFA 3 1 1.6 2 No – 33.9 Yes
2 RFA 3 1 2.7 1 No – 47.0 No
3 RFA 4 7 3.2 3 Yes 46.0 52.7 Yes
4 RFA 3 4 3.5 9 Yes 4.9 29.4 No
5 RFA 4 1 5.0 1 Yes 1.7 3.8 Yes
6 RFA 2 2 5.0 2 Yes 3.8 17.9 Yes
7 RFA 3 1 5.9 3 Yes 32.2 40.0 Yes
8 Hepatic resection (laparoscopic) 3 1 2.0 3 No – 64.5 Yes
9 Hepatic resection (open) 2 1 5.0 2 Yes 8.0 9.9 Yes
10 Aborted 4 >10 0.5 2 Yes – 21.6 No
11 Aborted 3 >10 0.5 2 Yes – 16.0 Yes
12 Aborted 3 >10 2.0 3 Yes – 67.0 Yes
13 Aborted 3 >10 3.0 1 Yes – 5.2 Yes
14 Aborted 2 1 4.0 2 Yes – 21.9 Yes
15 Aborted 4 6 4.0 1 Yes – 36.5 No
16 Aborted 3 >10 5.0 1 Yes – 3.2 Yes
17 Aborted 3 1 >5 3 Yes – 42.5 Yes
ASA, American Association of Anesthesiologists classification; IOUS, intra-operative ultrasound; LOS, Length of stay in hospital; RFA, radiofrequency
ablation; HR, hepatic Resection; LN, lymph nodes.
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hepatic remnant. Patients diagnosed with BCLM generally have
such a poor prognosis that treatment options are often palliative,
and the risk of major post-operative morbidity associated with
hepatic resection may not be warranted.
Minimally invasive procedures such as RFA have proven valu-
able in selected patients with isolated hepatic metastases and can be
utilized in patients who are not candidates for hepatic resection.12
RFA is associated with a low rate of post-operative morbidity and
can be performed percutaneously, laparoscopically or during open
surgery. The majority of the published studies describing RFA for
BCLM utilize the percutaneous approach. During percutaneous
RFA, the ablation probe is placed directly into the tumour under
CT guidance. Percutanous RFA is limited in that peritoneal as well
as new hepatic metastases cannot be directly visualized before
ablation. Smaller lesions or peritoneal metastases which may not
enhance on pre-operative imaging can often only be identified
Table 3 Median, 1-year, 3-year and 5-year survival as reported in the literature for patients who underwent chemotherapy alone, hepatic
resection or radiofrequency ablation for breast cancer liver metastases
Treatment Author Year No. of
patients
Median
survival
1-year
survival
3-year
survival
5-year
survival
Chemotherapy Stehlin, et al.29 1988 62 16 NR 12.7 2.8
Chemotherapy Gregory, et al.3 1993 271 4.5 NR NR NR
Chemotherapy Paridaens, et al.26 2000 29 22.7 NR NR NR
Chemotherapy Biganzoli, et al.25 2002 20 27.1 NR NR NR
Chemotherapy Sharma, et al.28 2003 11 6.5 NR NR NR
Chemotherapy Pentheroudakis, et al.27 2005 500 16.3 NR NR 8.5 (projected)
Hepatic resection Schneebaum, et al.30 1994 6 42 NR NR NR
Hepatic resection Raab, et al.31 1998 34 27 NR NR 18.4
Hepatic resection Seifert, et al.32 1999 15 57 100 71.4 53.6
Hepatic resection Kondo, et al.33 2000 6 NR NR 60 40
Hepatic resection Maksan, et al.34 2000 9 NR NR NR 51 (projected)
Hepatic resection Santoro, et al.35 2000 15 44 NR NR 38.3
Hepatic resection Selzner, et al.36 2000 17 24 NR NR 22
Hepatic resection Yoshimoto, et al.37 2000 25 34.3 NR 71 (2-year) 27
Hepatic resection Pocard, et al.38 2000 49 42 86 49 NR
Hepatic resection Carlini, et al.39 2002 17 53 NR NR 46
Hepatic resection Elias, et al.40 2003 54 34 NR 50 34
Hepatic resection Arena and Ferrero41 2004 17 NR 92 52 41
Hepatic resection Vlastos, et al.11 2004 31 63 NR 86 (2-year) 61
Hepatic resection Okaro, et al.42 2005 6 31 NR NR NR
Hepatic resection D' Annibale, et al.43 2005 18 32 NR NR 30
Hepatic resection Ercolani, et al.44 2005 21 40.3 NR 53.9 24.6
Hepatic resection Sakamoto, et al.45 2005 34 36 NR 52 21
Hepatic resection Adam, et al.22 2006 85 32 NR NR 37
Hepatic resection Caralt, et al.46 2008 12 35.9 100 79 33
Hepatic resection Lubrano, et al.9 2008 16 42 94 61 33
Hepatic resection Furka, et al.47 2008 17 19 NR NR NR
Hepatic resection Thelen, et al.48 2008 39 NR 77 50 42
RFA – Percutaneous Livraghi, et al.18 2001 24 NR NR NR NR
RFA – Laparoscopic Berber, et al.13 2005 10 51 NR NR NR
RFA – Percutaneous/Laparoscopic Amersi, et al.12 2006 9 30.1 NR NR NR
RFA – Percutaneous Lawes, et al.17 2006 19 9 NR NR NR
RFA – Percutaneous Sofocleous, et al.23 2007 12 60 100 70 30
RFA – Percutaneous Gunabushanam, et al.15 2007 14 NR 64 NR NR
RFA – Percutaneous Jakobs, et al.16 2009 43 58.6 NR NR NR
RFA – Percutaneous Meloni, et al.49 2009 52 29.9 68 43 27
NR, not reported; RFA, radiofrequency ablation. Inclusion criteria >5 patients reported.
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intra-operatively under direct visualization. A laparoscopic
approach allows for more accurate staging with direct visualization
and typically requires only two 10-mm incisions. In the present
study, 8 out of 17 patients who were felt to have metastatic disease
confined to the liver, which was potentially resectable, were discov-
ered to have widely metastatic or unresectable lesions.
This 47% incidence of untreatable disease identified during
SL/IOUS is higher than that reported in most series for BCLM.
Adam et al. found that in 108 patients taken to the operating room
for surgical management of BCLM, 34% of patients had more
disease than anticipated by pre-operative imaging, although only
21% were ultimately considered untreatable.22 However, the
present study included patients who were not candidates for
resection, but were candidates for RFA, accounting for 2 of the 8
aborted procedures. Had these patients been removed from the
analysis, the aborted procedure rate would be 40%. Still, 6 of 17
patients in our series had disease not manageable by surgical
intervention, leading to the conclusion that SL/IOUS is necessary
before surgical management of BCLM.
Within the current study there were no RFA treatment site
failures. Five patients who underwent RFA developed disease pro-
gression elsewhere in the liver. The median time to disease pro-
gression in these patients was 17.7 months. The rate of regional
progression after treatment with RFA reported in this series is
similar to other studies reporting outcomes of BCLM in the pub-
lished literature, which range from 50–58%.15,18 One of the two
patients who underwent treatment with hepatic resection, pre-
sented with regional recurrence 8.0 months post-operatively. This
patient chose to undergo pallative chemotherapy, and died shortly
after. The second patient remained disease-free, and died at 65
months of unrelated causes.
In the present study, the median survival for patients treated
with either hepatic resection or laparoscopic RFA was 40.0
months. These data are similar to other non-randomized retro-
spective studies published in the literature (Table 3). It has been
reported that the median survival for patients with BCLM who
undergo treatment with either hepatic resection or RFA ranges
from 19–63 months and 9–60 months, respectively.12,23 This sug-
gests that median survival for patients who undergo laparoscopic
RFA or hepatic resection is longer than that of patients treated
with chemotherapy alone (range, 4.5–27.1 months), and may
provide some benefit to a select group of patients with BCLM by
delaying disease progression and prolonging survival.3,24–29
Conclusion
The present study clearly demonstrates the importance of
SL/IOUS before locoregional intervention for patients with
BCLM. It also suggests that laparoscopic RFA and hepatic resec-
tion are safe surgical treatments in patients with BCLM. Further,
the use of RFA led to no treatment site failures and low morbidity,
suggesting that it may be an acceptable alternative to surgical
resection in selected patients.
The number of patients in this series is small and the follow-up
is relatively short, making it difficult to draw a meaningful con-
clusion regarding the appropriateness of aggressive surgical man-
agement in patients with BCLM.
The authors’ current practice, guided by this series review and
the existing literature, is to laparoscopically stage all patients being
considered for surgical mangement of BCLM. Resection and/or
RFA are selectively pursued in patients with four or fewer lesions.
Lesions less than 3 cm in diameter may be considered for RFA.
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